Brief Title
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Official Title
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Brief Summary
The available data indicate that Ceritinib has substantial anti-tumor activity in patients
with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC).
This trial will investigate the potential of Ceritinib in patients with advanced
gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no
available therapeutic option.
Detailed Description
This is a single-arm, open-label, multicenter, phase II study of ceritinib in adult patients
with ALK- and ROS1 activated colorectal, cholangiocarcinoma, pancreatic, hepatic, gastric, or
esophageal adenocarcinoma. An estimated 500 patients will be screened for ALK and ROS1 by
fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) per institutional
standard of care (SOC), and/or ALK/ROS1 by next-generation sequencing (NGS). At least 30
identified patients will be treated with ceritinib per protocol. Treatment with ceritinib
will continue until patient experiences unacceptable toxicity that precludes further
treatment, discontinues treatment at the discretion of the investigator or patient, starts a
new anticancer therapy and/or dies.
Male and female patients aged 18 or over that have colorectal adenocarcinoma,
cholangiocarcinoma, pancreatic, hepatocellular, gastric or esophageal adenocarcinoma that
contain an activated ALK gene due to rearrangement, mutation, amplification, translocation or
other mechanisms. Patients must have been pretreated with cytotoxic chemotherapy.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Clinical Benefit Rate (CBR) of ceritinib, as defined as the percentage of patients who have achieved complete response, partial response, and stable disease at 2 months per RECIST 1.1) to ceritinib by investigator assessment
Secondary Outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Condition
Colorectal Adenocarcinoma
Intervention
ceritinib
Study Arms / Comparison Groups
ceritinib
Description: Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
4
Start Date
December 2015
Completion Date
March 29, 2018
Primary Completion Date
March 29, 2018
Eligibility Criteria
Inclusion Criteria:
1. Histologically or cytologically confirmed diagnosis of inoperable colorectal
adenocarcinoma, pancreatic, hepatocellular, cholangiocarcinoma, small bowel, gastric
or esophageal adenocarcinoma that carries an activated ALK or ROS1 pathway
2. Age 18 years or older at the time of informed consent.
3. Patients must have received at least 1 line of cytotoxic chemotherapy
4. Patients must have archival tissue sample available, collected either at the time of
diagnosis or any time since.
- If archival tissue is unavailable, patient must be eligible and willing to undergo a
fresh tissue biopsy
5. Patients must have recovered from all toxicities related to prior anticancer therapies
to grade ≤ 2 (CTCAE v 4.03) provided that concomitant medication is given prior to
initiation of treatment with LDK378, except for patients with grade 2 nausea/vomiting
and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to
participate in the study. Additionally, patients with any grade of alopecia are
allowed on treatment.
6. Cohort Expansion Phase: Patient must have measurable lesions as defined by RECIST
version 1.1 criteria.
7. ECOG performance status 0-2
8. Patients must have normal organ and marrow function as defined below: Bone marrow
function defined as the following: An absolute neutrophil count ≥ (ANC) 1,500/mcl.
Platelets ≥ 75,000/mcl. Hemoglobin ≥ 8 g/dl.
9. Renal function defined as the following: Serum creatinine less than or equal to 1.5 x
institutional upper limit normal (ULN). Calculated or measured creatinine clearance
(CrCL) ≥ 30 mL/min
10. Hepatic function defined as the following: Serum total bilirubin < 1.5 x ULN. AST
(SGOT), ALT (SGPT), and alkaline phosphatase ≤ 3.0 x ULN. Serum albumin ≥ 2.5 g/dl. If
liver involvement, AST, ALT, and alkaline phosphatase ≤ 5.0 x ULN.
11. Serum amylase ≤ 2 x ULN and serum lipase ≤ 1 x ULN
12. Fasting plasma glucose ≤175 mg/dL (≤9.8 mmol/L)
13. Patient must have the following laboratory values or have the following laboratory
values corrected with supplements to be within normal limits at screening:
- Potassium ≥ lower limit of normal (LLN)
- Magnesium ≥ LLN
- Phosphorus ≥ LLN
- Total calcium (corrected for serum albumin) ≥ LLN
14. A male subject of fathering potential must use an adequate method of contraception to
avoid conception throughout the study [and for up to 12 weeks after the last dose of
study drug] to minimize the risk of pregnancy. If the partner is pregnant or
breastfeeding, the subject must use a condom. A condom is required to be used also by
vasectomized men in order to prevent delivery of the drug via seminal fluid.
15. Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for up to 12 weeks after the
last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative
serum or urine pregnancy test within 72 hours before the start of the investigational
product. Highly effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of
the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal are not acceptable methods of
contraception.
- Female sterilization (have had surgical bilateral oophorectomy with or without
hysterectomy) or tubal ligation at least six weeks before taking study treatment.
In case of oophorectomy alone, only when the reproductive status of the woman has
been confirmed by follow up hormone level assessment.
- Male sterilization (at least 6 months prior to screening) with the appropriate
post-vasectomy documentation of the absence of sperm in the ejaculate. For female
subjects on the study the vasectomized male partner should be the sole partner
for that subject.
- Combination of any two of the following (a+b or a+c or b+c):
- Use of oral, injected or implanted hormonal methods of contraception or other
forms of hormonal contraception that have comparable efficacy (failure rate <
1%), for example hormone vaginal ring or transdermal hormone contraception.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault
caps) with spermicidal foam/gel/film/cream/vaginal suppository.
In case of use of oral contraception, women should have been stable on the same pill
for a minimum of 3 months before taking study treatment.
Women are considered post-menopausal and not of child bearing potential if they have
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile
(e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral
oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior
to screening. In the case of oophorectomy alone, only when the reproductive status of
the woman has been confirmed by follow up hormone level assessment is she considered
not of child bearing potential.
16. Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
1. Patients who have had chemotherapy or radiotherapy within 3 weeks (4 weeks for
radiotherapy to the lung fields and 6 weeks for nitrosoureas or mitomycin C) prior to
entering the study or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier.
2. Patients with known hypersensitivity to any of the excipients of ceritinib
(microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and
magnesium stearate)
3. Prior therapy with ceritinib or other ALK or ROS1 inhibitor agents
4. Patients who are currently receiving treatment with warfarin sodium (Coumadin®) or any
other coumarin-derivative anti-coagulants.
5. Patients with symptomatic CNS metastases who are neurologically unstable or have
required increasing doses of steroids within the 1 week prior to study entry to manage
CNS symptoms.
6. Impairment of GI function or GI disease that may significantly alter the absorption of
ceritinib
7. History of pancreatitis or history of increased amylase or lipase that was due to
pancreatic disease.
8. Patients with known history of extensive disseminated bilateral interstitial fibrosis
or interstitial lung disease, including a history of pneumonitis, hypersensitivity
pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically
significant radiation pneumonitis (i.e. affecting activities of daily living or
requiring therapeutic intervention).
9. Cardiac conditions as follows:
- Active coronary artery disease, unstable or newly diagnosed angina or myocardial
infarction less than 6 months prior to first study drug administration.
- Class II-IV New York Heart Association (NYHA) congestive heart failure.
- Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
digoxin
- QTc (Frederica) prolongation > 470 msec.
- Subjects with valvular heart disease CTCAE (Version 4.0) Grade 2.
- Known left ventricular ejection fraction (LVEF) < 50%.
- Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg
and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without
anti-hypertensive medication
10. Receiving medications that meet one of the following criteria and that cannot be
discontinued at least 1 week prior to the start of treatment with LDK378 and for the
duration of participation:
- Medication with a known risk of prolonging the QT interval or inducing Torsades
de Pointes (please refer to
http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm)
- Strong inhibitors or strong inducers of CYP3A4/5 (please refer to
http://medicine.iupui.edu/flockhart/table.htm or
http://www.druginteractioninfo.org)
- Medications with a low therapeutic index that are primarily metabolized by
CYP3A4/5, and/or CYP2C9 (please refer to
http://medicine.iupui.edu/flockhart/table.htm or
http://www.druginteractioninfo.org)
- Therapeutic doses of warfarin sodium (Coumadin) or any other coumarin-derived
anti-coagulant. Anti-coagulants not derived from warfarin are allowed (e.g.,
dabigatran, rivaroxaban, apixaban).
- Unstable or increasing doses of corticosteroids
- Enzyme-inducing anti-convulsive agents
- Herbal supplements
11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris (Canadian
Cardiovascular Society grade II-IV despite medical therapy), cardiac arrhythmia,
active bleeding diatheses, or psychiatric illness/social situations that would limit
compliance with study requirements.
12. Major surgical procedure, open biopsy, or significant traumatic injury less than 4
weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle
aspiration) within 1 week from first dose of first study drug administration.
13. Known inability to swallow up to five LDK378 capsules daily.
14. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Christopher Lieu, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02638909
Organization ID
NOV-ALK-01
Responsible Party
Sponsor
Study Sponsor
Criterium, Inc.
Collaborators
University of Colorado, Denver
Study Sponsor
Christopher Lieu, MD, Principal Investigator, Criterium Inc., d.b.a. Academic GI Cancer Consortium (AGICC)
Verification Date
March 2018